Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Market Analysis and Insights: Global Prescription/Rx Sunglass Market
Due to the COVID-19 pandemic, the global Prescription/Rx Sunglass market size is estimated to be worth US$ 2734.7 million in 2022 and is forecast to a readjusted size of US$ 3116.2 million by 2028 with a CAGR of 2.2% during the review period. Fully considering the economic change by this health crisis, Glass accounting for % of the Prescription/Rx Sunglass global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hazardous Environments segment is altered to an % CAGR throughout this forecast period.
China Prescription/Rx Sunglass market size is valued at US$ million in 2021, while the US and Europe Prescription/Rx Sunglass are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Prescription/Rx Sunglass landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Prescription/Rx Sunglass include Luxottica (Italy), Safilo (France), Charmant (US), Marchon (US), Fielmann (Germany), De Rigo (Italy), Bausch & Lomb (US), Carl Zeiss (Germany) and Essilor (France), etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Prescription/Rx Sunglass Scope and Segment
Prescription/Rx Sunglass market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Prescription/Rx Sunglass market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Glass
CR-39
Polycarbonate
Polyurethane
Segment by Application
Hazardous Environments
Others
By Company
Luxottica (Italy)
Safilo (France)
Charmant (US)
Marchon (US)
Fielmann (Germany)
De Rigo (Italy)
Bausch & Lomb (US)
Carl Zeiss (Germany)
Essilor (France)
Rodenstock (Germany)
Hoya Corporation (Japan)
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Due to the COVID-19 pandemic, the global Prescription/Rx Sunglass market size is estimated to be worth US$ 2734.7 million in 2022 and is forecast to a readjusted size of US$ 3116.2 million by 2028 with a CAGR of 2.2% during the review period. Fully considering the economic change by this health crisis, Glass accounting for % of the Prescription/Rx Sunglass global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hazardous Environments segment is altered to an % CAGR throughout this forecast period.
China Prescription/Rx Sunglass market size is valued at US$ million in 2021, while the US and Europe Prescription/Rx Sunglass are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Prescription/Rx Sunglass landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Prescription/Rx Sunglass include Luxottica (Italy), Safilo (France), Charmant (US), Marchon (US), Fielmann (Germany), De Rigo (Italy), Bausch & Lomb (US), Carl Zeiss (Germany) and Essilor (France), etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Prescription/Rx Sunglass Scope and Segment
Prescription/Rx Sunglass market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Prescription/Rx Sunglass market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Glass
CR-39
Polycarbonate
Polyurethane
Segment by Application
Hazardous Environments
Others
By Company
Luxottica (Italy)
Safilo (France)
Charmant (US)
Marchon (US)
Fielmann (Germany)
De Rigo (Italy)
Bausch & Lomb (US)
Carl Zeiss (Germany)
Essilor (France)
Rodenstock (Germany)
Hoya Corporation (Japan)
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
